Neurocrine Biosciences posts Q3 2025 results update

Neurocrine Biosciences, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

Neurocrine Biosciences, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025. The company disclosed this by filing a current report and attaching the full earnings press release as Exhibit 99.1. The press release, dated October 28, 2025, contains the detailed figures and discussion of its results of operations and financial condition for the quarter.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neurocrine Biosciences (NBIX) announce in this 8-K?

Neurocrine Biosciences announced that it has released its financial results for the third quarter ended September 30, 2025, and attached the related earnings press release as Exhibit 99.1.

Which period do the latest Neurocrine Biosciences (NBIX) results cover?

The results cover the company’s financial performance for the third quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 financial results for NBIX?

The detailed Q3 2025 financial results are provided in the press release filed as Exhibit 99.1 to this current report.

Does this Neurocrine Biosciences 8-K make the Q3 2025 press release part of other SEC filings?

The company states that, under applicable rules, the information in this report and Exhibit 99.1 is not deemed “filed” or incorporated by reference into other securities filings unless specifically referenced.

Who signed this Neurocrine Biosciences Q3 2025 results 8-K?

The report was signed on behalf of Neurocrine Biosciences, Inc. by Matthew C. Abernethy, Chief Financial Officer and Principal Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/28/2025 - 04:02 PM EDT Learn about SEC filing dates

false000091447500009144752025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-22705
(Commission
File Number)

33-0525145
(IRS Employer
Identification No.)

6027 Edgewood Bend Court

San Diego, CA

(Address of principal executive offices)

92130

(Zip Code)

(858) 617-7600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

NBIX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 28, 2025, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit						Description
99.1						Press Release dated October 28, 2025
104						Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUROCRINE BIOSCIENCES, INC.
Dated: October 28, 2025			/s/ Matthew C. Abernethy
			Matthew C. Abernethy
			Chief Financial Officer (Duly authorized officer and Principle Financial Officer)